Carcinoembryonic antigen as an independent prognostic factor of recurrence and survival in patients resected for colorectal liver metastases: A systematic review

Diseases of the Colon and Rectum

Volumn 44, Issue 12, 2001, Pages 1791-1799

  Watine, Joseph ^c   Miédougé, Marcel ^a   Friedberg, Bruno ^b  

^a CHU PURPAN   (France)

^b Laboratoire de Biologie Polyvalente   (France)

^c Centre Hospitalier Général   (France)

Author keywords

CEA; Colorectal cancer; Hepatic resection; Laboratory expertise; Prognosis; Statistical expertise; Survival

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ARTICLE; ASSAY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; HUMAN; LIVER METASTASIS; MALE; MEDICAL LITERATURE; PREOPERATIVE EVALUATION; PROGNOSIS; QUALITY CONTROL; REPRODUCIBILITY;

EID: 0035660907     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02234457     Document Type: Article

References (48)

1. Surgical treatment of liver metastases in patients with colorectal cancer
2. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy
3. Intraoperative determinants of unresectability for patients with colorectal hepatic metastases
4. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer
5. Indicators for treatment strategies of colorectal liver metastases
6. Hepatic resection of colorectal metastases: Influence of clinical factors and adjuvant intraperitoneal 5-fluorouracil via Tenckhoff catheter on survival
7. The natural history, of hepatic metastases from colorectal cancer: A comparison with resective treatment
8. Resection of liver metastases from colorectal cancer: Are there any truly significant clinical prognosticators?
9. The future of prognostic factors in outcome prediction for patients with cancer
10. Hepatic resection for metastatic colorectal adenocarcinoma: A proposal of a prognostic scoring system
11. Clinical practice and guidelines for the use of tumor markers in breast and colorectal cancer
12. Evidence-based laboratory medicine: Supporting decision-making
13. Systematic reviewing in laboratory medicine. Position paper from the IFCC committee on systematic reviewing in laboratory medicine
14. Meta-analyses of studies of the diagnostic accuracy of laboratory tests: A review of the concepts and methods
15. Evidence-based illiteracy or illiterate evidence
16. Hepatic resection for colorectal metastases: Analysis of prognostic factors
17. Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases
18. One hundred patients with hepatic metastases from colorectal cancer treated by resection: Analysis of prognostic determinants
19. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases
20. Pre- and post-operative carcinoembryonic antigen determinations in hepatic resection for colorectal metastases: Predictive value and implications for adjuvant treatment based on multivariate analysis
21. Long-term survival following resection of colorectal hepatic metastases
22. The relationship between prognosis and CEA-dt after hepatic resection in patients with colorectal carcinomas
23. Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients
24. Resection of colorectal liver metastases: 25-Year experience
25. Registry of hepatic metastases. Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of patterns of recurrence
26. Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma
27. Resection of colorectal liver metastases
28. Prognostic factors after cryotherapy for hepatic metastases from colorectal cancer
29. The influence of intraoperative hypotension and perioperative blood transfusion on disease-free survival in patients with complete resection for colorectal liver metastases
30. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fiuorouracil, leucovorin, oxaliplatin and surgery
31. Recursive partitioning and amalgamation (RECPAM) for censored survival data: Criteria for tree selection
32. Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer
33. Analytical quality specifications for serum lactate dehydrogenase isoenzyme 1 based on clinical goals
34. Guide to the EC4 register European Clinical Chemist
35. Need for revisiting the concept of reference values
36. Preanalytical factors and their influence on analytical quality specifications
37. Major disagreements between immunoassays of carcinoembryonic antigen may be caused by nonspecific cross-reacting antigen 2 (NCA-2)
38. Reaction profiles of seven enzyme immunoassay kits for carcinoembryonic antigen (CEA) analyzed with purified preparations of CEA and related normal antigens
39. Reducing interference from heterophilic antibodies in a two-site immunoassay for carcinoembryonic antigen (CEA) by using a human/mouse chimeric antibody to CEA as the tracer
40. Comparison of a CEA-EIA assay based on monoclonal antibody with a CEA-RIA assay with polyclonal antiserum
41. Human antimurine antibody interference in measurement of carcinoembryonic antigen assessed with a double-antibody enzyme immunoassay
42. Prognostic factors in colorectat cancer
43. Carcinoembryonic antigen facilitates experimental metastasis through a mechanism that does not involve adhesion to liver cells
44. Characteristics of carcinoembryonic antigen (CEA) expressed in different cell types: Evidence that CEA can function as an adhesion molecule and as a repulsion molecule
45. Reducing unnecessary laboratory use with new test request form: Example of tumour markers
46. Prognostic significance of pre-operative serum CA 19.9 assay in patients with colorectal carcinoma
47. The association of pre-operative serum tumor markers with Dukes' stage and survival in colorectal cancer